Last reviewed · How we verify
HLX301
At a glance
| Generic name | HLX301 |
|---|---|
| Also known as | A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody |
| Sponsor | Shanghai Henlius Biotech |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma (PHASE1, PHASE2)
- HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HLX301 CI brief — competitive landscape report
- HLX301 updates RSS · CI watch RSS
- Shanghai Henlius Biotech portfolio CI